U.S. Markets closed

Jasper Therapeutics, Inc. (JSPR)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.6500+0.0664 (+11.38%)
At close: 04:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.5836
Bid0.6299 x 1100
Ask0.6700 x 1300
Day's Range0.5400 - 0.6684
52 Week Range0.5400 - 10.1900
Avg. Volume65,876
Market Cap24.605M
Beta (5Y Monthly)1.10
PE Ratio (TTM)N/A
EPS (TTM)-0.8070
Earnings DateNov 10, 2022 - Nov 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.00
  • GlobeNewswire

    Jasper Therapeutics Reports Third Quarter 2022 Financial Results and Provides a Corporate Update

    Positive Clinical Data Presented at IEWP Annual Meeting from Investigator Sponsored Study of JSP191 Conditioning Showed 100% Donor Chimerism in First Two Fanconi Anemia PatientsFast Track Designation Granted to JSP191 for Treatment of Patients with Severe Combined Immunodeficiency (SCID) Undergoing Allogeneic Hematopoietic Stem Cell TransplantFirst Patient Enrolled in New Study of Addition of JSP191 to Non-myleoablative Hematopoietic Stem Cell Transplantation for Sickle Cell Disease and Beta-Tha

  • GlobeNewswire

    Jasper Therapeutics Announces Positive Clinical Data from Investigator Sponsored Study of JSP191 Conditioning in Fanconi Anemia Patients at IEWP Annual Meeting

    The first two Fanconi Anemia patients receiving JSP191 achieved 100% donor chimerism JSP191 safe to infuse with no treatment-adverse events or toxicities observedREDWOOD CITY, Calif., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on hematopoietic cell transplant therapies, today announced that data from the company’s investigator-sponsored study of JSP191 as a conditioning agent in the treatment of Fanconi Anemia were presented at th

  • GlobeNewswire

    Jasper Therapeutics to Present at Upcoming Conferences

    REDWOOD CITY, Calif., Sept. 23, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on enabling cures with stem cell therapies, today announced that the Company will be participating in the following conferences in September. Cantor Fitzgerald Oncology, Hematology & HemeOnc Conference (New York City)Ronald Martell, CEO, will participate in a panel titled Addressing Challenges in Cell Therapy and Transplant Wednesday, September 28th, 2022, at 9:00AM